Please login to the form below

Not currently logged in
Email:
Password:

Priority review for AZ's thyroid cancer drug

The US Food and Drug Administration has granted priority review status for AstraZeneca's thyroid cancer drug vandetanib

The US Food and Drug Administration (FDA) has granted priority review status for AstraZeneca's (AZ) vandetanib – developed for the treatment of advanced medullary thyroid cancer (MTC).

The confirmation of the priority review came as the Anglo-Swedish drugmaker announced it had submitted the treatment for regulatory approval from both the FDA and the European Medicines Agency (EMA).

The applications follow AZ's phase III ZETA study to evaluate the safety and efficacy of the drug. In the trial, a once-daily dose of vandetanib 300mg was found to significantly extend progression-free survival in patients with MTC.

According to the American Cancer Society, there will be 44,000 new cases of thyroid cancer diagnosed in the US in 2010, with MTC accounting for five per cent of these.

Current treatments include surgery, although there are limited options for advanced stages of the disease. Radioiodine treatment – a common therapy in other forms of thyroid cancer – is not suitable for MTC.

AZ had previously submitted vandetanib for approval in both the US and EU for the treatment of non-small cell lung cancer under the brand name Zactima.

AZ withdrew both applications however after the drug demonstrated no overall survival advantage when used in addition to chemotherapy.

23rd September 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera

We live in a time of participation – patients actively involved in their own care recover faster and live longer....

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics